Roivant Sciences (ROIV) Income from Continuing Operations (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Income from Continuing Operations came in at 753651000.0 in Q4 2025, down 66.38% YoY from 2241716427.54 in Q4 2024, and down 353.9% on a QoQ basis from 166039000.0 in Q3 2025.
Roivant Sciences (ROIV) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Income from Continuing Operations data on file, last reported at 753651000.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 66.38% year-over-year to 753651000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1646569000.0 (down 137.38% YoY) and the FY2026 annual result came in at 397907000.0, up 45.47% from the prior year.
- Income from Continuing Operations fell to 753651000.0 in Q4 2025, from 166039000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 5126269000.0 in Q4 2023 to a low of 1054601000.0 in Q4 2022.
- A 5-year average of 3003866.67 and a median of 273911000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations tumbled 1167.12% — and 2023, when it soared 586.09%.
- Tracing ROIV's Income from Continuing Operations over 5 years: stood at 632803000.0 in 2021, then tumbled by 66.66% to 1054601000.0 in 2022, then soared by 586.09% to 5126269000.0 in 2023, then plunged by 108.84% to 452968000.0 in 2024, then sank by 66.38% to 753651000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 753651000.0 (Q4 2025), 166039000.0 (Q3 2025), and 273911000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -290.61 Mn |
| Dec 31, 2025 | -753.65 Mn |
| Sep 30, 2025 | -166.04 Mn |
| Jun 30, 2025 | -273.91 Mn |
| Dec 31, 2024 | -452.97 Mn |
| Sep 30, 2024 | -236.84 Mn |
| Jun 30, 2024 | -31.60 Mn |
| Dec 31, 2023 | 5.13 Bn |
| Sep 30, 2023 | -244.64 Mn |
| Jun 30, 2023 | -327.85 Mn |
| Dec 31, 2022 | -1.05 Bn |
| Sep 30, 2022 | -315.92 Mn |
| Jun 30, 2022 | -353.78 Mn |
| Dec 31, 2021 | -632.80 Mn |
| Sep 30, 2021 | -225.64 Mn |
| Jun 30, 2021 | -101.08 Mn |
| Dec 31, 2020 | -275.60 Mn |
| Sep 30, 2020 | -53.50 Mn |
| Jun 30, 2020 | -7.98 Mn |